Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14868799 | 0.81 | RAB9A (0.41) | RAB9ANPC1L3MBTL1 | |
| SCHEMBL24433774 | 0.74 | — | — | |
| SCHEMBL14868245 | 0.73 | RAB9A (0.43) | RAB9ANPC1L3MBTL1 | |
| SCHEMBL14868721 | 0.72 | RAB9A (0.46) | RAB9ANPC1L3MBTL1ADAM17 | |
| SCHEMBL14868754 | 0.70 | METAP2 (0.35) | RAB9ANPC1L3MBTL1 | |
| SCHEMBL14868618 | 0.70 | KMT2A (0.47) | — | |
| SCHEMBL14868528 | 0.70 | RIPK1 (0.47) | L3MBTL1ADAM17 | |
| SCHEMBL24433666 | 0.69 | — | — | |
| SCHEMBL14868683 | 0.68 | ADRA2A (0.47) | RAB9ANPC1ADAM17 | |
| SCHEMBL17198854 | 0.68 | ADRA2A (0.47) | RAB9ANPC1ADAM17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11759441-B2 | Biguanide compositions and methods of treating metabolic disorders | ANJI PHARMACEUTICALS INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20220151957-A1 | BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS | ANJI PHARMACEUTICALS INC. | 2022-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11759441-B2 | Biguanide compositions and methods of treating metabolic disorders | SLC5A2, SLC5A1, GPR119 | RAB9A 2425/4885NPC1 405/4885L3MBTL1 4566/4885 |
| US-20220151957-A1 | BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS | SLC5A2, SLC5A1, GPR119 | RAB9A 2425/4885NPC1 405/4885L3MBTL1 4566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.